Blood Coagulation Factor Inhibitors
"Blood Coagulation Factor Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria.
| Descriptor ID |
D019774
|
| MeSH Number(s) |
D23.113
|
| Concept/Terms |
Blood Coagulation Factor Inhibitors- Blood Coagulation Factor Inhibitors
- Inhibitor, Coagulation Factor, Blood
- Inhibitors, Coagulation Factor, Blood
- Inhibitor, Blood Coagulation Factor
- Inhibitors, Blood Coagulation Factor
|
Below are MeSH descriptors whose meaning is more general than "Blood Coagulation Factor Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Blood Coagulation Factor Inhibitors".
This graph shows the total number of publications written about "Blood Coagulation Factor Inhibitors" by people in this website by year, and whether "Blood Coagulation Factor Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Blood Coagulation Factor Inhibitors" by people in Profiles.
-
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
-
Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020 Oct; 50(3):580-586.
-
Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci. 2020 Sep; 24(17):9161-9168.
-
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019 Jun; 6(6):e295-e305.
-
Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. Clin Chem. 2019 02; 65(2):254-262.
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
-
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha. Haemophilia. 2018 09; 24(5):e372-e375.
-
Non-factor replacement therapy for haemophilia: a current update. Blood Transfus. 2018 09; 16(5):457-461.
-
Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus. 2018 11; 16(6):535-544.
-
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. Blood Transfus. 2018 02; 16(2):215-220.